title: Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).
authors.affiliation: Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA.
authors.forename: C Warren
authors.initials: CW
authors.lastname: Olanow
authors.forename: Philippe
authors.initials: P
authors.lastname: Damier
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Goetz
authors.forename: Thomas
authors.initials: T
authors.lastname: Mueller
authors.forename: John
authors.initials: J
authors.lastname: Nutt
authors.forename: Olivier
authors.initials: O
authors.lastname: Rascol
authors.forename: Alexandru
authors.initials: A
authors.lastname: Serbanescu
authors.forename: Frieda
authors.initials: F
authors.lastname: Deckers
authors.forename: Hermann
authors.initials: H
authors.lastname: Russ
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008499:Medical Records; D009930:Organic Chemicals; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D009930:Organic Chemicals; D007980:Levodopa; C443959:sarizotan